The Generation Scotland Electronic Health Record data resource is a key component of the Generation Scotland Scottish Family Health Study (GS:SFHS) 1 , a biobank conceived in 1999 (www.generationscotland.org) for the purpose of studying the genetics of health areas of current and projected public health importance. 2 GS:SFHS is a large, family-based, intensively-phenotyped cohort of volunteers from the general population across Scotland, UK.
The median age at recruitment was 47 for males and 48 for females, and the cohort has 99% white ethnicity. 1 Over 24 000 adults were recruited from 2006 to 2011, with broad and enduring written informed consent for biomedical research. Specific consent was obtained from 23 603 participants for GS:SFHS study data to be linked to their Scottish National Health Service (NHS) records, using their Community Health Index (CHI) number. This identifying number is used for NHS Scotland procedures (registrations, attendances, samples, prescribing and investigations) and allows healthcare records for individuals to be linked across time and location. 3 Here, we describe the NHS electronic health record (EHR) dataset on the sub-cohort of 20 032 GS:SFHS participants with consent and mechanism for record linkage plus extensive genetic (both directly measured and imputed genotype) data. Together with existing study phenotypes, including family history and environmental exposures such as smoking, the EHR is a rich resource of real world data that can be used in research to characterise the health trajectory of participants, available at low cost and a high degree of timeliness, matched to DNA, urine and serum samples and detailed genetic information.
Data resources and population coverage
The numbers of participants with full phenotype data, genome-wide genotype and consent for record linkage are shown in Figure 1 . Research data (baseline and derived subsequent to recruitment) are stored by the Generation Scotland biobank in a study database and EHR data by the NHS. EHR data can be extracted by the NHS National Services Scotland electronic 3 Data Research and Innovation Service (eDRIS) on GS:SFHS participants using their CHI number and put into a secure data centre, such as a safe haven. This data can be analysed through secure access protocols then de-identified individual-level study and routine medical data brought together for specific approved research projects, in line with the expectations of the participants. GS:SFHS probands were first approached through their General Practitioner (GP) using the CHI database, which has a unique number for each individual in the >96% of the Scottish population registered with a GP. 3 Those who indicated that they and one or more of their relatives were considering participation were sent an information leaflet, a consent form and a questionnaire. The details of this recruitment of 24 090 participants to GS:SFHS have been described previously. 1 DNA was extracted from the blood or saliva of participants 4 , and samples were genotyped using a genome-wide SNP array (Illumina OmniExpressExome). 5 A subset of participants was selected for genotyping, consisting of those individuals who were born in the UK, had Caucasian ethnicity, had full baseline phenotype data available from a visit to a GS:SFHS research clinic in Aberdeen, Dundee, Glasgow or Perth, and had consented for their data to be linked to their NHS records. 5 The total number of individuals genotyped was 20 128, of which 20 032 passed additional genetic quality control filtering. 
Coverage dates for biochemistry EHRs vary regionally across

Data Collected
The study phenotype (cohort profile) 1 and subsequent genotype data (both directly typed and imputed to the Haplotype Reference Consortium release 1.1 panel) 5 
have both been described
previously and an open access phenotype data dictionary is available (http://dx.doi.org/10.7488/ds/2057). This paper provides the first detailed description of the electronic health record datasets available in GS:SFHS through record linkage and the process to access this data. The structured, coded variables in the biochemistry, prescribing and morbidity datasets in particular are highly valuable for a genetics biobank such as GS:SFHS.
Access to a wealth of other more specialized datasets including cancer, maternity inpatient and mental health (http://www.ndc.scot.nhs.uk/National-Datasets/index.asp) is also possible through the same straightforward and transparent application process. 6 A table listing examples of routine and research data sets to which GS:SFHS data and samples can be linked anonymously, using the CHI number, has been published. 1 Once a proposal has been approved, researchers are provided with pseudo-anonymised data extracts. CHI numbers are replaced by unique study numbers and personal identifying information is removed. Numbers of participant records currently available for each of the main EHR data categories, and the proportion with genome-wide genotype data, are illustrated in Figure 2 . 
Data Resource Use
The genome-wide genetic data in GS:SFHS has been used in a large number of research projects across a wide range of study phenotypes that have generated over 100 publications to date (http://www.ed.ac.uk/generation-scotland/news-events/publications). The first research 6 paper to use record linkage in GS:SFHS, on the impact of parental diabetes on offspring health, was published in 2015. 8 . This information has been used in haplotype association analyses of MDD 10 , stratification of MDD into genetic subgroups 11 and genome-wide meta-analyses of stratified depression. 12 Data science has great potential as a catalyst for improved mental health recognition, understanding, support and outcomes. 13, 14 A second example is a genome-wide association study (GWAS) of serum urate in the Tayside regional subset of the cohort. 5 Uric acid is a medically relevant phenotype measure, with high levels leading to the formation of monosodium urate crystals that can cause gout.
Hyperuricaemia has additionally been associated with a variety of diseases including type 2 diabetes, hypertension and cardiovascular disease, while hypouricaemia has been linked to neurodegenerative disorders including Parkinson's disease and Alzheimer's disease. 15 GWAS of uric acid was performed using EHR-derived measures from 2077 individuals 5 and shows the strong signal in the SLC2A9 gene previously reported using data gathered specifically for research 16, 17, 18 . This positive control confirmed that the EHR-derived biochemistry data can be suitable for population-based analyses, despite being collected for clinical purposes. The initial analysis has now been extended into the Glasgow regional subset of the cohort (Figure 1) , extending the number of individuals with both genotype data and at least one uric acid measurement to 3162, within the total of 17 877 participants where genetic and biochemistry data can be accessed ( Figure 2 ).
Hospital admission, prescription and biochemistry EHRs can be used to infer disease status in
individuals after recruitment to the study has concluded, including for diseases that were not part of the initial data collection. One such example is gout, which was not explicitly included in the pre-clinical questionnaire, but with access to EHR data it is possible to ascertain gout status for participants in GS:SFHS. Not all individuals with hyperuricaemia develop gout, which may mean that other factors predispose individuals to a greater or lesser risk of disease progression. Identifying these factors could help inform targeted prevention and personalised management of the disease. The up-to-date status of risk factors available in GS:SFHS from EHR linkage makes it an excellent resource for a case-to-high-risk-control GWAS. A static study might incorrectly class an individual as a high-risk control simply because they did not develop gout until after data collection had concluded. Here, 420 gout cases have been identified through the use of urate lowering medication, obtained from the Scottish National Prescribing Information System (PIS). 7 Additional information can be obtained from the GS:SFHS baseline phenotype dataset, including self-reported use of medications and measures such as body mass index. This information, together with the range of risk factors available in the biochemistry, prescribing and morbidity (e.g. gout ICD-10 codes in SMR01) EHR datasets, will be used to select risk-matched individuals who have not developed gout, for a case-control GWAS of GS:SFHS participants.
Strengths and Weaknesses
Data quality and costs
Extensive and detailed phenotyping, including longitudinal biochemistry data, is of considerable utility in understanding underlying biological or disease mechanisms. However, 8 this data can be difficult and expensive to obtain directly, as measures require different assays and the quantity of donated samples (e.g. serum, plasma) is finite in a biobank such as GS.
Collecting longitudinal samples requires ongoing recontact with study participants, which is both expensive and time-consuming. Access to routine EHR data is therefore of great value in genetic research across broad-based medical specialities, 19 as exemplified by the Electronic Medical Records and Genomics (eMERGE) network. 20 Scotland has some of the most comprehensive health service data in the world. Few other countries can lay claim to national indexed data of such high quality and consistency. The Generation Scotland phenotype, genotype and imputed data have been subject to extensive quality control and are research ready. The EHR biochemistry data was generated in accredited NHS laboratories for clinical use, therefore the measures are accurate, with internal and external quality control and quality assurance processes in place for all tests and investigations. Over time assay methods, instrumentation and automation protocols will have changed, but outputs have to show consistency for clinical diagnostic purposes. On occasion an arithmetic correction has to be applied, for example some of the uric acid values in the EHR dataset are in mmol/L, while most are in the more widely used µmol/L.
The biochemistry data was generated as part of routine medical care by the NHS, and only modest cost recovery charges are made to provide access to it for research purposes. This compares favourably with the costs of commissioning new tests on blood, serum or plasma samples. The Generation Scotland data access process also incurs a cost recovery charge.
An NHS Data Quality Assurance team is responsible for ensuring Scottish Morbidity Record Although the data available is extensive, some gaps exist. For example, data from primary care (the Scottish Primary Care Information Resource, SPIRE) 21 may become available for linkage in future. This would be particularly useful for research on conditions such as dementia where much of the initial health service contact is with general practitioners.
Medical imaging data (X-rays, CT scans etc) held in an NHS Scotland Picture Archiving and Communications System (http://www.nisg.scot.nhs.uk/currently-supporting/pacs-and-ris) may also become available for research in due course. Another weakness is that any features of illness that occur outside NHS Scotland will not be documented. However, the availability of GS:SFHS study data that was collected at recruitment, together with the range of different types of data available longitudinally in the EHR, mean that (for example) accurate classification of cases and controls can be achieved.
Data Resource Access
Generation Scotland operates a managed data access process including an online application form (http://www.ed.ac.uk/generation-scotland/using-resources/access-to-resources). Five of the authors of this paper sit on the Generation Scotland Access Committee (GSAC) that assesses applications for collaborative access to the data described. Proposals are reviewed by the GSAC and, following approval, researchers and their host institutions sign a data and/or material transfer agreement with GS. A favourable opinion from a Research Ethics Committee (REC) is in place for research using study data (and samples), as GS:SFHS is a Research Tissue Bank. Research that includes access to EHR data is notified to the REC by the GS management team on behalf of the researchers, through a substantial amendment. Manhattan plot displays the results of a genome-wide association analysis using genotyped SNPs and EHR-derived serum urate measurements, as an example of how the datasets can be can be used together in genetic research by approved researchers. The single highest serum urate reading was taken for each participant, with covariates and methods for accounting for relatedness as previously described. 5 The −log10 (P-value) is plotted on the y-axis, and chromosomal location is plotted on the x-axis. The genome-wide significance threshold accounting for multiple testing (p-value < 5 x 10 -8 ) is indicated by a red line, while suggestive significance (p-value < 10 -5 ) is indicated by a blue line. 
